MNPR - Monopar Therapeutics

53.24
-0.060   -0.113%

Share volume: 198,334
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$53.30
-0.06
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 18%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.67%
1 Month
-3.64%
3 Months
-25.44%
6 Months
-34.73%
1 Year
19.45%
2 Year
8,003.50%
Key data
Stock price
$53.24
P/E Ratio 
0.00
DAY RANGE
$52.30 - $53.78
EPS 
-$1.33
52 WEEK RANGE
$28.40 - $105.00
52 WEEK CHANGE
$24.65
MARKET CAP 
503.901 M
YIELD 
N/A
SHARES OUTSTANDING 
6.683 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.03
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$201,056
AVERAGE 30 VOLUME 
$186,878
Company detail
CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Recent news